Abbvie Stock News

The acquisition will expand AbbVie’s neuroscience portfolio with Syndesi’s lead drug candidate for treating symptoms associated with Alzheimer’s disease. The post AbbVie buys Syndesi Therapeutics for up to $1bn appeared first on Silicon Republic .

AbbVie acquires Novo Holdings portfolio company Syndesi Submitted 01/03/2022 - 3:42pm Syndesi Therapeutics (Syndesi), a portfolio company of international life sciences investor Novo Holdings, has been acquired by AbbVie for up to USD1 billion in total deal value with USD130 million upfront. Syndesi was created in 2018 as the result of a close collaboration between Novo Seeds, the company creation arm of Novo Holdings, and UCB Pharma, the Belgium-based global pharmaceutical company. The investment in Syndesi is an integral part of Novo Seeds’ approach to new venture formation by co-leading spinouts from pharmaceutical companies based on assets that are no longer in-line with the corporation’s overall strategy. Like this article? Sign up to our free newsletter Author Profile Related Topics Deals Intelligence

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio AbbVie (NYSE: ABBV) today announced…

AbbVie (ABBV) has acquired of Syndesi Therapeutics, giving the former access to a portfolio of novel modulators of the synaptic vesicle protein 2A (SV2A), including lead…

NORTH CHICAGO, Ill., March 1, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Cowen 42nd Annual Health Care Conference on Tuesday, March 8, 2021. Robert A. Michael, vice chairman, finance and commercial operations and chief financial officer, Michael E. Severino, M.D.,…

Shares of AbbVie were down 0.6% in premarket trading on Tuesday after the company completed a $1 billion acquisition of Syndesi Therapeutics SA. Syndesi is developing treatments for cognitive impairment and other symptoms associated with Alzheimer''s disease and major depressive disorder. Per the terms of the deal, AbbVie will make a $130 million upfront payment, with an additional $870 million in milestone payments at hand. AbbVie''s stock is up 36.3% over the past year, while the broader S&P 500 has gained 14.4%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

GENT, BELGIUM, March 1, 2022 /⁨EINPresswire.com⁩/ -- V-Bio Ventures today announced the completion of the acquisition of its portfolio company Syndesi Therapeutics SA by AbbVie (NYSE: ABBV), which will help to expand AbbVie’s neuroscience portfolio …

Belgian company Syndesi Therapeutics was backed by Irish VC Fountain Healthcare on spin-out

Abbvie Inc said on Monday the U.S. health agency extended the review period for the expanded use of its newer psoriasis drug Skyrizi by three months, citing the need for more time to review additional data submitted by the company.

NORTH CHICAGO, Ill., Feb. 28, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has extended its review period for SKYRIZI® (risankizumab-rzaa) for the treatment of moderate to severe Crohn''s disease in patients 16 years and older….

Someone with a lot of money to spend has taken a bearish stance on AbbVie (NYSE: ABBV ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with ABBV, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 20 uncommon options trades for AbbVie. This isn''t normal. The overall sentiment of these big-money traders is split between 45% bullish and 55%, bearish. Out of all of the special options we uncovered, 6 are puts, for a total amount of $3,848,499, and 14 are calls, for … Full story available on Benzinga.com

UBS has cut AbbVie (ABBV) to neutral from buy based on the stocks current valuation and near-term pipeline catalysts.

AbbVie Inc (NYSE: ABBV ) has submitted a supplemental application to the FDA for Imbruvica (ibrutinib) for chronic graft versus host disease (cGVHD). The application covers Imbruvica for pediatric and adolescent patients one year and older with cGVHD after the failure of one or more lines of systemic therapy. A New Drug Application (NDA) was also submitted for an oral suspension formulation … Full story available on Benzinga.com

Jim Cramer and Jeff Marks compare chipmakers including Marvell, AMD, and Qualcomm. They also discuss what they think will be next for UPS, Abbvie and Chevron stocks. Finally, Jim and Jeff take a look at software companies reporting earnings this week, Workday and Salesforce.

We are locking in more profits in AbbVie on Monday morning following the stock’s impressive run of outperformance recently. Source link Investing Club: We’re capitalizing on one of our drug stocks’ incredible run, selling some shares